Health / Investing

Add as a preferred source on Google

Candel Pushes Prostate Cancer Application Target to Mid-2027

The company cited assay-refinement timelines and said the schedule remains subject to its dialogue with the FDA. Hagens Berman has opened an inquiry into Candel’s disclosures.

Updated 2 min read
A laboratory technician handles a vial beside assay equipment at a biotechnology laboratory in Cambridge, Massachusetts. (AI-generated image / EconoTimes)
A laboratory technician handles a vial beside assay equipment at a biotechnology laboratory in Cambridge, Massachusetts. (AI-generated image / EconoTimes)

Candel Therapeutics has shifted its planned U.S. application for an investigational prostate cancer treatment to mid-2027, delaying a regulatory milestone for the biotechnology company and drawing an investor-disclosure inquiry from a plaintiffs’ law firm.

Candel said Nov. 12 that it expects to submit a biologics license application, or BLA, for aglatimagene in mid-2027. The company attributed the timing to timelines for certain assay refinement and said the target remains subject to the outcome of its ongoing dialogue with the U.S. Food and Drug Administration (FDA). A BLA seeks FDA approval to market a biologic product.

The new target replaces the fourth-quarter 2026 submission date in an earlier Candel investor presentation. The company did not specify the assay work or describe the FDA’s position.

FinanceCharts lists Candel shares as closing at $8.39 on Nov. 12. It reported a $6.20 close the next day, a 26.1% decline.

Hagens Berman Sobol Shapiro LLP said it opened an investigation into Candel’s disclosures about the application’s status and timing. The firm cited Candel’s earlier statements about the filing schedule. Reed Kathrein, the partner leading the inquiry, said it would review the history of the assay work and the company’s prior statements about its timetable. The investigation announcement does not establish wrongdoing or say that a lawsuit has been filed.

Aglatimagene is an investigational treatment for localized prostate cancer. Candel said its phase 3 trial was conducted under a Special Protocol Assessment agreed with the FDA. The company also said batches from its process-validation campaign were undergoing testing and were intended for commercial use, pending BLA approval.

Candel reported $203.1 million in cash and cash equivalents as of Sept. 30, 2026, and said it expected that amount to fund its current operating plan into the second quarter of 2028. Its stated application target is mid-2027, conditional on assay refinement and the FDA dialogue.

Related articles

View all